Making Rare Disease Treatments Economically Sustainable
Access to rare disease treatments depends on proving their clinical value and economic impact. Our Health Economics & Outcomes Research (HEOR) and Market Access teams work directly with national reimbursement agencies (e.g., NICE in the UK) to develop compelling value arguments for our therapies.
Health Economics & Market Access
We provide:
Health technology assessment (HTA) dossiers and cost-effectiveness models
Engagement strategies for payers, commissioners, and pricing authorities
Real-world evidence generation to support long-term clinical and financial value
Collaboration with patient advocacy groups to support policy change
We advocate for sustainable pricing and reimbursement models that ensure patients receive care — and health systems receive value.
Public Sector & Government Partnerships
Collaborating with Health Authorities to Serve Public Needs
Aegerion Pharmaceuticals UK is an experienced and trusted government partner, supplying vital orphan drugs through public tenders, framework agreements, and named-patient supply programs. Our work with NHS Trusts and other health bodies reflects our commitment to public health priorities and access equity.
